Daiichi Sankyo soars on $22bn Merck cancer drugs deal

Shares in Japan’s Daiichi Sankyo soared on Friday after the pharma group announced a major cancer drug deal with US giant Merck worth up to $22 billion. Merck will pay Daiichi for the rights to three drugs in development known as antibody-drug conjugates (ADCs), which attack cancer cells without damaging surrounding healthy ones. Daiichi shares briefly surged almost 18 percent […]
» Read more